Fasoracetam is a racetam developed by Nippon Shinyaku in Japan as NS-105 for cerebrovascular disease, studied through the 1990s without being approved.
Amounts reported for Fasoracetam are listed under Reported protocols, each with its source and study kind. No amount ladder is inferred from them. This is educational source context, not a protocol or recommendation.
Enter a target amount only from your own reviewed source. The calculator can convert it into concentration, volume and device markings, but it will not infer an amount from product availability or another compound.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
Human study rows are described per source under Reported protocols; they belong to their trial populations and are not a general amount.
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
What published studies and recent community write-ups report about amounts, timing and course length. 3 clinical, 2 preclinical and 3 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Clinical3 rows | |||||
| Open-label dose-escalation study in adolescents with ADHD30 adolescents aged 12-17 with ADHD and mutations in mGluR network genes | Single doses of 50-800 mg for pharmacokinetics; then 50 mg, 100 mg, 200 mg and 400 mg twice daily in successive weeks | Twice daily | Oral | 5 weeks: a single-blind placebo week followed by 4 weeks of symptom-driven escalationNone described | Nature Communications (PubMed)2018 |
| Clinical Global Impression scores improved significantly from baseline to week 5 and parental ratings improved in the subgroup with the most disruptive variants, with no more adverse events on drug than during the placebo week. The study was open-label and uncontrolled after week 1, so the improvement cannot be separated from expectation. Registered as NCT02286817. | |||||
| Randomised phase 2/3 trial in adolescents with ADHD (registry record)101 adolescents aged 12-17 with ADHD and copy-number variants in mGluR network genes, enrolled at Kennedy Krieger Institute | 100, 200 or 400 mg | Twice daily, optimised over the first 4 weeks then held | Oral hard gelatin capsules | 6 weeksNone described | ClinicalTrials.gov2016 |
| This double-blind, placebo-controlled trial sponsored by Aevi Genomic Medicine ran from June 2016 to February 2017 with change in ADHD-RS-5 total score and CGI-I response as co-primary outcomes. The registry lists results with no serious adverse events among nine adverse event types. It remains the only controlled efficacy trial of fasoracetam in any population, and the compound has not been approved for any use. | |||||
| Pharmacokinetics in elderly versus young men14 healthy men, 7 aged 68-79 and 7 aged 20-32 | 100 mg tablet | Single dose after breakfast | Oral | Single doseNot applicable | International Journal of Clinical Pharmacology Research (PubMed)1999 |
| Peak concentration was about 40 percent higher and total exposure about 70 percent higher in the elderly group, with clearance reduced mainly through lower renal clearance that tracked creatinine clearance. The authors advise careful observation in elderly patients, which matters because the compound is cleared by the kidney. | |||||
| Preclinical2 rows | |||||
| Memory disruption models in ratsRats with scopolamine, basal forebrain lesion, AF64A, baclofen, ischaemia or electroconvulsive shock induced amnesia | 10 mg/kg for the acetylcholine release and choline uptake measurements | Single administration before testing | Oral | AcuteNot applicable | Pharmacology, Biochemistry and Behavior (PubMed)1999 |
| NS-105 reversed memory disruption across every cholinergic-deficit model tested and also reversed baclofen-induced amnesia, which comparator drugs did not. It increased cortical acetylcholine release and high-affinity choline uptake without changing choline acetyltransferase activity, pointing to cholinergic facilitation plus suppression of GABA-B responses. | |||||
| Antidepressant models and GABA-B receptor upregulation in ratsRats in forced swimming and learned helplessness tests | 1-100 mg/kg | Single and repeated administration | Oral | Repeated dosing in the learned helplessness and receptor-binding experimentsNot applicable | European Journal of Pharmacology (PubMed)1997 |
| NS-105 reduced immobility in the forced swim test and reversed escape failure after repeated dosing, and repeated administration increased the number of cortical GABA-B receptors without touching monoamine uptake or levels. This paper is the origin of the community claim that fasoracetam restores GABA-B sensitivity after phenibut or baclofen use; the finding is in rats. | |||||
| Community-reported3 rows | |||||
| Community oral and sublingual protocols | 10-30 mg by mouth or 5-20 mg sublingually | Twice daily, morning and early afternoon | Oral, or held under the tongue for 60-90 seconds | 8 weeks on2 weeks off | Community resource2026 |
| This stack-planning site suggests starting at 10 mg twice daily and notes that clinical ADHD trials used far higher doses. Its sublingual claim of better bioavailability has no published pharmacokinetic support, and the cycle is convention rather than evidence. It lists sedation, headache and low motivation at higher doses as reported side effects. | |||||
| Community dose range against the trial dose | 20-100 mg per day as a nootropic; 100-400 mg twice daily in the ADHD trials | Once or twice daily | Oral or sublingual | Not specifiedNot specified | Community resource2026 |
| This UK reference page separates the 20-100 mg a day used by hobbyists from the 100-400 mg twice daily used in the Aevi trials, and reports that users describe GABA-B related effects as building over days to weeks. It records the compound as unapproved in every country and notes that long-term safety for nootropic use is not established. | |||||
| Vendor research-use listing | 40 mg per capsule, 60 capsules per bottle | Not stated (sold for laboratory research only) | Oral capsule format | Not statedNot stated | Community resource2026 |
| Vendor claim. The vendor sells fasoracetam as 40 mg capsules with an ISO 17025 laboratory certificate for lot FAS01 (HPLC purity 99.04 percent, 41.16 mg measured). The page cites the 2018 Nature Communications study but gives no dosing information and states the product is not for human consumption. | |||||
Plus 3 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.
Fasoracetam is a racetam developed by Nippon Shinyaku in Japan as NS-105 for cerebrovascular disease, studied through the 1990s without being approved. It was revived as NFC-1 by Aevi Genomic Medicine for adolescents with ADHD who carry metabotropic glutamate receptor gene variants, with a 2018 open-label study at up to 400 mg twice daily and a registered phase 2/3 trial of 100-400 mg twice daily. Rat studies attribute its effects to cholinergic facilitation and upregulation of GABA-B receptors, and the 10-100 mg a day quoted online is well below any human trial dose.
These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.
Neuroplasticity, cognition, stress and sleep models.
Clinical Global Impression scores improved significantly from baseline to week 5 and parental ratings improved in the subgroup with the most disruptive variants, with no more adverse events on drug than during the.
This double-blind, placebo-controlled trial sponsored by Aevi Genomic Medicine ran from June 2016 to February 2017 with change in ADHD-RS-5 total score and CGI-I response as co-primary outcomes. The registry lists.
Peak concentration was about 40 percent higher and total exposure about 70 percent higher in the elderly group, with clearance reduced mainly through lower renal clearance that tracked creatinine clearance. The authors.
NS-105 reversed memory disruption across every cholinergic-deficit model tested and also reversed baclofen-induced amnesia, which comparator drugs did not. It increased cortical acetylcholine release and high-affinity.
NS-105 reduced immobility in the forced swim test and reversed escape failure after repeated dosing, and repeated administration increased the number of cortical GABA-B receptors without touching monoamine uptake or.
Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.
3 protocol rows on this page come from human trials, trial registrations, regulator labels or reviews of human data. Approval status and populations are stated per row.
2 protocol rows describe animal, cell or toxicology work. Amounts from these rows do not translate to people.
3 rows record what blogs, vendor write-ups or forums describe for Fasoracetam. None has been verified against primary literature.
Sequence, synonyms and registry identifiers as recorded in PubChem, the National Library of Medicine's open chemistry database. Formula, mass and CAS number are summarized at the top of the page.
NS-105, LAM-105, NFC-1, AEVI-001, N-(5-Oxo-D-prolyl)piperidine, (R)-1-((5-Oxo-2-pyrrolidinyl)carbonyl)piperidine, UNII 42O8UF5CJB, CHEMBL2106179
GOWRRBABHQUJMX-MRVPVSSYSA-N
(5R)-5-(piperidine-1-carbonyl)pyrrolidin-2-one
6 curated references, each with its journal, year and study model, plus 3 community resources reported but not linked.